文献速递骨质疏松与代谢性骨病

绝经前特发性骨质疏松症序贯治疗停止后的骨密度与骨重建

Bone density and remodeling after discontinuation of sequential therapy for premenopausal idiopathic osteoporosis.
PubMed 文献 · Osteoporos Int · 2025-12-14

本研究在19例绝经前特发性骨质疏松症女性中观察特立帕肽-地舒单抗序贯治疗后双膦酸盐维持1年、再停药观察1年的骨密度变化。停药后6个月内脊柱骨密度下降4.2±2.5%、全髋下降1.4±2.1%(均p<0.05),约半数参与者因骨丢失或低骨密度重启双膦酸盐;但骨密度仍显著高于治疗前基线。

要点

  • 特立帕肽-地舒单抗序贯治疗使脊柱骨密度增加23±9%、全髋增加12±7%。
  • 双膦酸盐维持1年后停药,6个月内脊柱骨密度下降4.2±2.5%、全髋下降1.4±2.1%(均p<0.05)。
  • 停药后骨密度仍显著高于治疗前基线,但双膦酸盐最佳疗程需进一步研究。

核心结论

  • 在绝经前特发性骨质疏松症女性中,特立帕肽-地舒单抗序贯治疗带来大幅骨量增加,并经1年双膦酸盐治疗得以维持。
  • 停用双膦酸盐后前6个月出现显著骨丢失,约半数参与者因此重启治疗,但骨密度仍显著高于治疗前水平。
  • 绝经前特发性骨质疏松症女性停用地舒单抗后双膦酸盐的最佳疗程需进一步研究。

研究设计与样本

  • 观察性延伸研究(双膦酸盐延伸研究第2年),纳入19例绝经前特发性骨质疏松症女性,年龄44±8岁。
  • 受试者此前接受特立帕肽-地舒单抗序贯治疗,随后双膦酸盐(阿仑膦酸钠或唑来膦酸)治疗1年(BES第1年),再停药观察1年(BES第2年)。
  • 每6个月以DXA测量骨密度并检测血清CTX。
  • 试验注册号:ClinicalTrials.gov NCT03396315。

主要发现

  • 特立帕肽-地舒单抗序贯治疗后,脊柱骨密度增加23±9%,全髋增加12±7%。
  • BES第1年双膦酸盐治疗期间,6个月和12个月时骨密度与CTX均无显著变化。
  • BES第2年12-18个月,脊柱骨密度下降4.2±2.5%、全髋下降1.4±2.1%(均p<0.05),其他部位保持稳定;CTX升高218±210 pg/ml(p<0.05)。
  • 18个月时,10例参与者因骨丢失或低骨密度重启双膦酸盐,9例继续观察;至BES第2年末,两组脊柱骨密度均稳定。
  • 脊柱和髋部骨密度仍显著且大幅高于开始特立帕肽前水平。

局限性

  • 原文指出,绝经前特发性骨质疏松症女性停用地舒单抗后双膦酸盐的最佳疗程需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: In premenopausal IOP, BMD gains on teriparatide-denosumab were maintained on bisphosphonate over 1 year. In 19 followed after bisphosphonate, there was a significant bone loss over 6M, leading to retreatment in some. BMD remained significantly above pretreatment baseline. In premenopausal IOP, the optimal duration of bisphosphonate after denosumab requires further study. We have previously reported that sequential teriparatide-denosumab resulted in large BMD increases in premenopausal women with idiopathic osteoporosis (IOP), and that BMD remained stable with bisphosphonate (alendronate or zoledronate) for 1 year after denosumab cessation (Bisphosphonate Extension Study; BES Year 1). To determine the durability of this effect, an observation year (BES Year 2) off therapy was planned. PARTICIPANTS: 19 women, aged 44 ± 8, with premenopausal IOP. MEASURES: BMD by DXA, serum CTX every 6 months (M). RESULTS: On sequential teriparatide-denosumab, BMD increased by 23 ± 9% at the spine and 12 ± 7% at the total hip. In BES Year 1 on bisphosphonate, BMD and CTX did not change significantly at 6M or 12M. From 12-18M of BES Year 2, BMD declined by 4.2 ± 2.5% at the spine and 1.4 ± 2.1% at the total hip (both p < 0.05); other sites remained stable. CTX increased by 218 ± 210 pg/ml (p < 0.05). At 18M, ten participants resumed bisphosphonates because of bone loss or low BMD and nine continued observation. By the end of BES Year 2, spine BMD stabilized in both groups. BMD at the spine and hip was significantly and substantially higher than before beginning teriparatide. CONCLUSION: In premenopausal women with IOP, sequential therapy with teriparatide-denosumab was associated with large gains in bone mass that were maintained by 1 year of bisphosphonate treatment. There was significant bone loss during the first 6 months after discontinuing bisphosphonates, leading to retreatment in about half the participants. Despite this bone loss, BMD remained significantly above pretreatment levels. In premenopausal women with IOP, the optimal duration of bisphosphonate therapy after denosumab cessation requires further study. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03396315.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Cohen A, Kamanda-Kosseh M, Rawal R, et al. Bone density and remodeling after discontinuation of sequential therapy for premenopausal idiopathic osteoporosis. Osteoporos Int. 2025. PMID: 41392041. doi:10.1007/s00198-025-07755-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。